系统综述与基于模型的分析:URAT1抑制剂的肾脏安全风险是否完全由降尿酸疗效决定
本文通过系统综述随机对照试验并结合基于模型的分析,比较不同URAT1抑制剂的肾脏安全性与降尿酸疗效。结果显示,氯沙坦类URAT1抑制剂的肾脏安全事件发生率差异较大,降尿酸疗效并非肾脏安全风险的独立决定因素,结构差异可能起作用;不良肾脏效应呈剂量依赖性,联用高剂量黄嘌呤氧化酶抑制剂可通过减少肾脏尿酸排泄显著降低肾脏安全风险。
要点
- 不同URAT1抑制剂的肾脏安全事件发生率差异明显,降尿酸疗效并非其独立决定因素。
- URAT1抑制剂的不良肾脏效应呈剂量依赖性,结构差异可能解释安全性差异。
- 联用高剂量黄嘌呤氧化酶抑制剂可减少肾脏尿酸排泄,从而显著降低肾脏安全风险。
核心结论
- 降尿酸疗效不是不同URAT1抑制剂肾脏安全风险的独立因素,结构差异可能是原因;不良肾脏效应呈剂量依赖性,联用高剂量黄嘌呤氧化酶抑制剂可通过减少肾脏尿酸排泄显著降低肾脏安全风险。
研究设计与样本
- 系统综述已发表的URAT1抑制剂随机对照试验,考察肾脏安全事件发生率;并进行基于模型的分析,预测代表性URAT1抑制剂的降尿酸疗效。
主要发现
- 高尿酸血症患者中,lesinurad、verinurad、dotinurad、SHR4640和苯溴马隆的总体肾脏安全事件发生率分别为11.2%(142/1264)、12.0%(34/284)、0.5%(2/421)、2.3%(5/213)和1.3%(5/393)。
- 采用半机制药代动力学/药效学模型建立lesinurad、verinurad、dotinurad和SHR4640单用或联用黄嘌呤氧化酶抑制剂的剂量-暴露-效应关系。
- 每日一次给药时,中间剂量的疗效排序为2 mg dotinurad > 10 mg verinurad > 5 mg SHR4640 > 400 mg lesinurad。
- 80 mg非布司他和600 mg别嘌醇分别使24小时累积肾脏尿酸排泄量降低48.4%和48.3%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Renal safety risk is currently an important factor that hinders the development of uric acid transporter 1 (URAT1) inhibitors. This study aimed to compare the renal safety and uric acid-lowering efficacy of different URAT1 inhibitors and clarify the association between them. METHODS: A systematic review of published randomized controlled trials on URAT1 inhibitors was conducted to investigate the incidence of renal safety events. A model-based analysis was performed to predict the uric acid-lowering efficacy of representative URAT1 inhibitors. RESULTS: The overall renal safety event incidences of lesinurad, verinurad, dotinurad, SHR4640, and benzbromarone in patients with hyperuricemia were 11.2 % (142/1264), 12.0 % (34/284), 0.5 % (2/421), 2.3 % (5/213), and 1.3 % (5/393), respectively. A semi-mechanistic pharmacokinetic/pharmacodynamic model was used to establish the dose-exposure-effect relationship of lesinurad, verinurad, dotinurad, and SHR4640 with or without the combination of xanthine oxidase inhibitors (XOIs). The efficacy ranking of the intermediate dose of URAT1 inhibitors with once-daily dosing was 2 mg dotinurad > 10 mg verinurad > 5 mg SHR4640 > 400 mg lesinurad. The combination of 80 mg febuxostat and 600 mg allopurinol reduced the 24-h cumulative renal uric acid excretion by 48.4 % and 48.3 %, respectively. CONCLUSION: Uric acid-lowering efficacy is not an independent factor for the renal safety risk of different URAT1 inhibitors, and structural differences could be responsible for the difference. The adverse renal effects of URAT1 inhibitors are dose-dependent, and the combination with high doses of XOIs can significantly reduce the renal safety risk by reducing uric acid excretion by the kidneys.
引用
- Qu Y, Yu Y, Pan J, et al. Systematic review and model-based analysis to identify whether renal safety risks of URAT1 inhibitors are fully determined by uric acid-lowering efficacies. Semin Arthritis Rheum. 2023. PMID: 37866004. doi:10.1016/j.semarthrit.2023.152279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。